NASDAQ: TNXP
Tonix Pharmaceuticals Holding Corp Stock

$31.98-2.56 (-7.41%)
Updated Jun 13, 2025
TNXP Price
$31.98
Fair Value Price
$21.27
Market Cap
$234.24M
52 Week Low
$6.76
52 Week High
$137.25
P/E
-0.02x
P/B
1.3x
P/S
10.55x
PEG
N/A
Dividend Yield
N/A
Revenue
$10.04M
Earnings
-$131.93M
Gross Margin
29.8%
Operating Margin
-1,313.87%
Profit Margin
-1,313.9%
Debt to Equity
0.07
Operating Cash Flow
-$60M
Beta
1.14
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

TNXP Overview

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine TNXP's potential to beat the market

CHold
  • Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More

Zen Rating Component Grades

F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
TNXP
Ranked
#180 of 464

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important TNXP news, forecast changes, insider trades & much more!

TNXP News

Overview

Due Diligence Score

Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TNXP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

TNXP ($31.98) is overvalued by 50.35% relative to our estimate of its Fair Value price of $21.27 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
TNXP ($31.98) is not significantly undervalued (50.35%) relative to our estimate of its Fair Value price of $21.27 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
TNXP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more TNXP due diligence checks available for Premium users.

Valuation

TNXP fair value

Fair Value of TNXP stock based on Discounted Cash Flow (DCF)

Price
$31.98
Fair Value
$21.27
Overvalued by
50.35%
TNXP ($31.98) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
TNXP ($31.98) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
TNXP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

TNXP price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-0.02x
Industry
-108.97x
Market
31.36x

TNXP price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
1.3x
Industry
4.66x
TNXP is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

TNXP's financial health

Profit margin

Revenue
$2.4M
Net Income
-$16.8M
Profit Margin
-692.8%
TNXP's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
TNXP's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$192.9M
Liabilities
$12.5M
Debt to equity
0.07
TNXP's short-term assets ($149.57M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TNXP's short-term assets ($149.57M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TNXP's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
TNXP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$16.6M
Investing
-$6.0k
Financing
$49.5M
TNXP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

TNXP vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
TNXPC$234.24M-7.41%-0.02x1.30x
AARDD$233.01M-2.89%N/A1.55x
TVRDC$230.47M-5.71%-0.82x-28.55x
TVGND$228.03M-2.36%-6.20x-29.54x
FHTXC$240.80M-4.85%-3.18x-3.91x

Tonix Pharmaceuticals Holding Stock FAQ

What is Tonix Pharmaceuticals Holding's quote symbol?

(NASDAQ: TNXP) Tonix Pharmaceuticals Holding trades on the NASDAQ under the ticker symbol TNXP. Tonix Pharmaceuticals Holding stock quotes can also be displayed as NASDAQ: TNXP.

If you're new to stock investing, here's how to buy Tonix Pharmaceuticals Holding stock.

What is the 52 week high and low for Tonix Pharmaceuticals Holding (NASDAQ: TNXP)?

(NASDAQ: TNXP) Tonix Pharmaceuticals Holding's 52-week high was $137.25, and its 52-week low was $6.76. It is currently -76.7% from its 52-week high and 373.08% from its 52-week low.

How much is Tonix Pharmaceuticals Holding stock worth today?

(NASDAQ: TNXP) Tonix Pharmaceuticals Holding currently has 7,324,670 outstanding shares. With Tonix Pharmaceuticals Holding stock trading at $31.98 per share, the total value of Tonix Pharmaceuticals Holding stock (market capitalization) is $234.24M.

Tonix Pharmaceuticals Holding stock was originally listed at a price of $30,000.00 in May 10, 2012. If you had invested in Tonix Pharmaceuticals Holding stock at $30,000.00, your return over the last 13 years would have been -99.89%, for an annualized return of -40.93% (not including any dividends or dividend reinvestments).

How much is Tonix Pharmaceuticals Holding's stock price per share?

(NASDAQ: TNXP) Tonix Pharmaceuticals Holding stock price per share is $31.98 today (as of Jun 13, 2025).

What is Tonix Pharmaceuticals Holding's Market Cap?

(NASDAQ: TNXP) Tonix Pharmaceuticals Holding's market cap is $234.24M, as of Jun 15, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Tonix Pharmaceuticals Holding's market cap is calculated by multiplying TNXP's current stock price of $31.98 by TNXP's total outstanding shares of 7,324,670.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.